News & Events about Dyne Therapeutics Inc.
Globe Newswire
2 months ago
- Company Presents Overviews of ACHIEVE and DELIVER Global Clinical Trials with Data Anticipated from Both Studies in the Second Half of 2023 - - FORCEPlatform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in a Severe In Vivo Model of Duchenne...
Globe Newswire
2 months ago
- Data Anticipated in the Second Half of 2023 from ACHIEVE Clinical Trial of DYNE-101 in DM1 and DELIVER Clinical Trial of DYNE-251 in DMD - WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing ...
Ticker Report
4 months ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Ticker Report
4 months ago
Dyne Therapeutics, Inc. (NASDAQ:DYN Get Rating) insider Jonathan Mcneill sold 10,000 shares of the businesss stock in a transaction that occurred on Wednesday, January 18th. The shares were sold at an average price of $14.03, for a total value of $140,300.00. Following the completion ...
Globe Newswire
4 months ago
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Joshua Brumm, president and chief ...